SOST and chronic kidney disease: Notably, the pathophysiologic links of Sclerostin with MBD in CKD have been recently claimed to explain the association with vascular calcification, cardiovascular disease and mortality [14,18,20], thus further increasing the clinical interest for this new biomarker.